Curative Biotechnology Outlines Its Strategic Vision
Innovative Steps Towards Enhanced Value Creation
Curative Biotechnology Inc. (OTC: CUBT), a forward-thinking biomedical firm, is thrilled to share vital updates about its strategic plans aimed at combatting degenerative eye disorders. With a clear focus on novel therapies, the company is committed to promising advancements that align with its core mission of developing impactful treatments.
Dear valued shareholders and prospective investors,
We are excited to provide you with an insightful update on our evolving business strategy and the roadmap ahead. Curative Biotech is diligently working towards optimizing our clinical approach, particularly regarding our flagship program: the metformin-based eye drops derived from our exclusive license with the National Eye Institute. We are eager to share essential modifications that promise to enrich our development trajectory while enhancing our economic stability.
Strategic Developments Driving Our Mission
1. Strategic Partnerships for Manufacturing and Development
Recognizing the importance of collaboration, Curative Biotech is actively pursuing a manufacturing and product development partnership pertinent to our metformin eye drops. This alliance is poised to:
- Significantly reduce operational risks associated with our clinical trials while ensuring a dependable supply chain for our products;
- Facilitate non-dilutive financial support through upfront capital and milestone payments;
- Expedite the commercialization pathway for critical treatments addressing intermediate Dry AMD and other degenerative eye conditions.
Negotiations with potential partners are currently underway, and we are optimistic about finalizing a partnership soon. However, there are no guarantees that these discussions will culminate in a formal agreement.
Our efforts don’t just stop with human treatments. We aim to expand our focus to veterinary medicine, particularly addressing vision impairments in dogs (K9). Our key targets include:
- Progressive Retinal Atrophy (PRA), which affects nearly six million dogs in the U.S.;
- Central Progressive Retinal Atrophy (CPRA), with around 80,000 new U.S. cases diagnosed annually.
CPRA shares symptomatic traits with human Dry AMD and presents a unique opportunity for accelerated approval from the FDA's Center for Veterinary Medicine (CVM). With streamlined trials, we expect that the positive data from our human studies will substantiate our claims of effectiveness.
The veterinary ophthalmic drug market is projected to reach between $1.5 billion and $2.0 billion each year, representing substantial unmet needs. While we are hopeful about utilizing our preclinical research for approval, the CVM's acceptance remains uncertain.
2. Adjustments to Capital Structure
In alignment with our strategic updates, we have taken decisive steps regarding our capital structure:
- Withdrawal of the previously planned S-1 public offering to focus on more immediate funding opportunities;
- Implementation of a revised 150-to-1 reverse stock split, replacing the earlier 400-to-1 structure.
The pending reverse split awaits FINRA's endorsement, which typically takes several weeks to process. We cannot guarantee outcomes regarding effect on our financial requirements.
Pathway to Enhanced Market Presence
Following the execution of our strategic manufacturing agreement and the updated reverse stock split, Curative Biotech plans to submit our application for uplisting to the OTCQB Venture Market. Key advantages to this move will include:
- Improved visibility and access for both individual and institutional investors;
- Increased transparency, which could enhance share liquidity;
- A strategic position for potential uplisting to a national exchange in the future.
Though we are optimistic about this uplisting, we cannot ensure that our application will be approved.
Conclusion of Our Strategic Update
This strategic reevaluation illustrates our commitment to establishing a well-structured, reduced-risk, and aligned future for Curative Biotech. We are confident that these strategic initiatives will foster progress within our clinical program and ultimately drive long-term value for our stakeholders.
Sincerely,
The Management Team of Curative Biotechnology
Future Updates from Curative Biotechnology
Shareholders and interested parties are welcomed to request future notifications by contacting us via email.
About Curative Biotechnology, Inc.
Curative Biotechnology, Inc. is dedicated to pioneering biomedical advancements for rare diseases, concentrating on innovative therapeutics that can transform patient care. With robust programs targeting degenerative eye diseases, infectious diseases, and neuro-oncology, Curative Biotech is committed to navigating critical therapy developments.
At the forefront is our degenerative eye disease initiative supported by an exclusive license from the National Eye Institute (NEI), with ambitious plans for a first-in-human clinical trial projected in 2026 under a Cooperative Research and Development Agreement (CRADA) with NEI.
Frequently Asked Questions
What is Curative Biotechnology's main focus?
Curative Biotechnology focuses on developing innovative treatments for rare diseases, specifically degenerative eye diseases.
What updates were announced regarding their strategic partnerships?
The company is seeking a manufacturing and product development sublicense agreement to enhance their clinical trial outputs.
What does the revised reverse stock split mean for shareholders?
The company has changed the reverse stock split ratio to 150-to-1 to better align with its strategic direction.
How will uplisting to OTCQB benefit the company?
Uplisting is expected to increase visibility, improve accessibility for investors, and potentially enhance liquidity of shares.
What are the prospects for veterinary treatment initiatives?
Curative Biotech plans to target canine eye diseases, especially Progressive Retinal Atrophy (PRA) and Central Progressive Retinal Atrophy (CPRA).
